By 2050, the death toll from antimicrobial resistance (AMR) will rise higher than that of cancer today. Due to the growing threat of AMR to public health worldwide, there is an urgent need for new, effective, and safer antibacterial therapies.

Our solution redesigns antibacterial medicines for the 21st century. Our core technology is a platform to rapidly generate antibacterials engineered to minimise the emergence of resistance, with minimal side effects and low-dose pharmacokinetics.